Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BP 002 - Brillian Pharma

Next Previous
X
Search
Drug Profile

BP 002 - Brillian Pharma

Alternative Names: BP-002 - Brillian Pharma

Latest Information Update: 06 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brillian Pharma
  • Class Antibacterials
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Clostridium difficile infections

Most Recent Events

  • 23 Jan 2024 Clinical trials in Clostridium difficile infections (In children) (PO), prior to January 2024 (Brillian Pharma pipeline, January 2024)
  • 23 Jan 2024 Brillian Pharma plans to launch BP 002 in Clostridium difficile infections in China in the first quarter of 2024 (Brillian Pharma pipeline, January 2024)
  • 23 Jan 2024 Brillian Pharma plans to launch BP 002 in Clostridium difficile infections in USA in the first quarter of 2024 (Brillian Pharma pipeline, January 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top